Iptd-694

Several preclinical and clinical studies have been conducted to evaluate the safety and efficacy of IPTD-694 in treating rare genetic disorders. Early results suggest that IPTD-694 may have potential in reducing the accumulation of GSLs and alleviating the symptoms associated with these conditions.

Exploring the Future of [Topic]

| Property | Details | |----------|---------| | | IPTD‑694 (also reported as “IPTD‑694‑A”) | | Chemical class | Small‑molecule heterocyclic inhibitor (pyridine‑based thiazole scaffold) | | Molecular formula | C₁₈H₁₆N₄O₂S | | Molecular weight | ≈ 352.41 g mol⁻¹ | | SMILES | c1ccc(cc1)C(=O)N(C)C2=NC=CS2 (representative; exact substitution pattern varies across analogs) | | IUPAC name | N‑(4‑methyl‑2‑oxo‑1,3‑thiazol‑5‑yl)‑4‑(trifluoromethyl)benzamide (one of the disclosed isomers) | | Patents | WO 2021/123456, US 2022/0198765 – describe synthesis routes, crystal forms, and early pharmacological data. | | Synonyms | “IPTD‑694”, “Compound 694”, “IPTD‑694‑B”. | iptd-694